CD4 and melanoma: The authors demonstrated that the tumor antigen-targeting mAb TA99, specific for the melanosomal polypeptide gp75 (the most abundant glycoprotein synthesized by pigmented melanocytes and melanomas) [80], increased the fraction of CD4+ and CD8+ T cells in the tumor microenvironment in B16F10 melanoma mouse model, as compared to mice treated with isotype control.